|
Society Of Urologic Oncology Position
Statement: Redefining The Management Of Hormone-Refractory Prostate Cancer
(CANCER, January 1, 2005, Vol. 103, pp. 11- 21.) (February 2005)
This nine page consensus statement, developed by eleven
leading specialists (including Dr. C. Higano, University of Washington)
with subsequent peer review, is a succinct and topically organized
up-to-date listing and discussion of treatment options. The authors define
HRPC broadly as the disease state in which PSA and/or clinical disease
progression develops during hormone therapy despite castrate levels of
testosterone.
The article is a handy reference for the clinician. It can serve as a
mental check list to ensure that the full range of validated options are
considered when faced with decisions in patient management. Strategies for
various situations are covered efficiently and often in several sentences,
but are well referenced as a guide for the search for more detailed
information. Sections on “Adjunctive Therapies”, “Bone Targeted
Therapies”, and “Hormonal Manipulation: Second-Line Hormonal Agents” are
examples of topical divisions. When compared to the NCCN Internet
guideline presentation for HRPC (nccn.org), this consensus article seems
more user friendly and informative.
Bottom Line:
The Urologic Oncology position statement could serve clinicians as a
useful quick office reference source for management options in the
treatment of HRPC.
«
Back to Article List
|
